uniQure

QURE · Nasdaq · Netherlands

Share price · QURE

$20.30-27.08 (-57.15%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.3M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when QURE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 29 Sep 2026-37.3%
  2. 24 Sep 2026-10.4%

    Nothing announced by QURE that day or the session before.

  3. 17 Jun 2026+78.4%
  4. 9 Mar 2026+26.1%

    Nothing announced by QURE that day or the session before.

  5. 6 Mar 2026+34.0%

    Nothing announced by QURE that day or the session before.

  6. 5 Mar 2026+17.8%

    Nothing announced by QURE that day or the session before.

  7. 2 Mar 2026-32.8%
  8. 26 Feb 2026-31.2%

    Nothing announced by QURE that day or the session before.

  9. 3 Feb 2026+12.6%

    Nothing announced by QURE that day or the session before.

Share of unusual movement by asset

For each asset, the share of QURE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Ifezuntirgene inilparvovec
events and moves
7shown from 8 days
AMT-260
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—7%
Other company news (earnings, financing, releases naming no asset)—81%
Sessions with no dated event—12%

Assets

(3 total)
3Total Assets
1Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
Factor IX gene delivery (hFIX-Padua)Gene therapy / editing
Hemophilia B
Phase 1/2
GRIK2 (GluK2-containing kainate receptor)Gene therapy / editing
Epilepsy
Phase 1/2
Huntingtin (HTT) geneGene therapy / editing
Huntington's Disease

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
AMT-260Phase 1/2Mesial Temporal Lobe Epilepsy
Est. primary completion 2026-11-30 · NCT06063850 · CT.gov ↗
What to watch
2028 (1)
October 2028 (1)
Est. primary completion 2028-10-04 · NCT06003387 · CT.gov ↗
What to watch
2029 (2)
March 2029 (1)
Ifezuntirgene inilparvovecPhase 1/2Huntington Disease
Est. primary completion 2029-03 · NCT05243017 · CT.gov ↗
What to watch
June 2029 (1)
Ifezuntirgene inilparvovecPhase 1/2Huntington's Disease
Est. primary completion 2029-06 · NCT04120493 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

1 May 2027FDA action dateIfezuntirgene inilparvovecPDUFA target action date of 2027-05-01 set for ifezuntirgene inilparvovec BLA
US, FDA · Source ↗

Recent

2 November 2026Filing acceptedIfezuntirgene inilparvovecFDA accepts BLA for ifezuntirgene inilparvovec in Huntington's disease
US, FDA · Source ↗
2 November 2026Priority reviewIfezuntirgene inilparvovecFDA grants priority review to ifezuntirgene inilparvovec BLA
US, FDA · Source ↗
29 September 2026Topline resultIfezuntirgene inilparvovec36- and 48-month data from Phase I/II studies of AMT-130
2 September 2026Filing submittedAMT-130 (ifezuntirgene inilparvovec)uniQure submits BLA for accelerated approval of AMT-130 in Huntington's disease
US, FDA · uniQure · Source ↗
Q3 2026Filing submittedIfezuntirgene inilparvovecMAA submitted to the MHRA
UK, MHRA · Source ↗
Q3 2026Filing acceptedIfezuntirgene inilparvovecMHRA validates the MAA
UK, MHRA · Source ↗
19 June 2026Topline resultAMT-260GenTLE Phase I/IIa: preliminary first-cohort data
uniQure · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$5.2M$36M$100M+ $570M short-term inv.$61M-$48M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$5.8M$34M$415M+ $397M short-term inv.$81M-$29M operating cash flowreport ↗
2026-Q1—$29M$142M+ $447M short-term inv.$54M-$38M operating cash flowreport ↗
2025-Q3$3.7M$34M$599M+ $97M short-term inv.$81M-$16M operating cash flowreport ↗
2025-Q2$5.3M$35M$255M+ $123M short-term inv.$38M-$40M operating cash flowreport ↗
2025-Q1$1.6M$36M$219M+ $192M short-term inv.$44M-$44M operating cash flowreport ↗
2024-Q3$2.3M$31M$253M+ $184M short-term inv.$44M-$37M operating cash flowreport ↗
2024-Q2$11M$34M$291M+ $237M short-term inv.$56M-$33M operating cash flowreport ↗
2024-Q1$8.5M$41M$246M+ $313M short-term inv.—-$61M operating cash flowreport ↗
2023-Q3$1.4M$65M$233M+ $429M short-term inv.—$39M operating cash flowreport ↗
2023-Q2$2.4M$46M$517M+ $115M short-term inv.—-$57M operating cash flowreport ↗
2023-Q1$5.3M$61M$157M+ $161M short-term inv.—-$78M operating cash flowreport ↗
2022-Q3$1.4M$48M$443M—-$49M operating cash flowreport ↗
2022-Q2$0.5M$46M$504M—-$16M operating cash flowreport ↗
2022-Q1$1.8M$45M$528M—-$26M operating cash flowreport ↗
2021-Q3$2.0M$36M$581M—-$40M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$16M$141M$82M+ $543M short-term inv.$50M-$178M operating cash flowreport ↗

uniQure reported FY2025 revenue of $16.1M, down 40.6% YoY, with R&D expense of $140.67M, down 2.2% YoY. The company ended the period with cash and equivalents of $81.8M, or approximately $622.5M including current investment securities, and reported a net loss of $198.97M ($3.46 diluted loss per ordinary share).

Management expects existing cash, cash equivalents, and investment securities to fund operations into the second half of 2029. On the pipeline, the FDA stated in a Type A meeting that AMT-130 Phase I/II data with an external control are not sufficient to support a marketing application and recommended a prospective, randomized, double-blind, sham-surgery-controlled study; uniQure plans to request a Type B meeting in Q2 2026. AMT-260 completed first-cohort enrollment with a second cohort underway and data expected in Q2 2026. AMT-191 showed durable, dose-dependent enzyme activity increases, though dosing in mid- and high-dose cohorts was paused after Grade 3 liver enzyme elevations, and AMT-162 enrollment remains on voluntary pause.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$27M$144M$160M+ $209M short-term inv.$60M-$183M operating cash flowreport ↗
2023-FY$16M$215M$245M+ $377M short-term inv.$77M-$146M operating cash flowreport ↗
2022-FY$106M$198M$231M+ $125M short-term inv.$32M-$145M operating cash flowreport ↗
2021-FY$524M$144M$559M—$288M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 53 sales ($20.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-06Meek David D. · directorOpen-market sale9,080$21.25$193KForm 4
2026-10-30Abi-Saab Walid · Chief Medical OfficerAward / grant18,750——Form 4
2026-07-02Kapusta Matthew C · director, CEO, Managing DirectorOption exercise21,082$19.39$409KForm 4
2026-07-02Kapusta Matthew C · director, CEO, Managing DirectorOpen-market sale9,200$44.43$409KForm 4
2026-07-02Kapusta Matthew C · director, CEO, Managing DirectorOpen-market sale4,282$45.43$195KForm 4
2026-07-02Kapusta Matthew C · director, CEO, Managing DirectorOpen-market sale7,600$45.89$349KForm 4
2026-07-02Kapusta Matthew C · director, CEO, Managing DirectorOption exercise (derivative)21,082——Form 4
2026-06-30Kaye Jack · directorOption exercise4,107$37.00$152KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 211 reporting institutions held 60.0M shares ($961.1M, 95.1% of shares outstanding).

#InstitutionSharesValue
1Avoro Capital Advisors LLC5,959,595$97.4M
2Aberdeen Group plc5,306,386$86.8M
3TWO SIGMA INVESTMENTS, LP2,675,871$43.8M
4RTW INVESTMENTS, LP2,586,356$42.3M
5JPMORGAN CHASE & CO2,837,466$41.8M
6STATE STREET CORP2,260,512$37.0M
7ORBIMED ADVISORS LLC2,136,149$34.9M
8FMR LLC1,743,808$28.5M
9BlackRock, Inc.1,733,458$28.3M
10MPM BIOIMPACT LLC1,369,231$22.4M
11Two Seas Capital LP1,300,000$21.3M
12GOLDMAN SACHS GROUP INC1,263,236$20.7M
13JENNISON ASSOCIATES LLC1,233,789$20.2M
14SUSQUEHANNA INTERNATIONAL GROUP, LLP1,002,800$16.4M
15Siren, L.L.C.1,000,000$16.4M